glp-1 obesity drug news today october 16 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care ISPOR 2025: Exploring reasons for

This interesting finding, occurring without weight loss, is consistent with preclinical and clinical studies showing weight-independent effects of GLP-1R agonism on liver steatosis 51,52,53

doi:10.1371/journal.pone.0187836 225

Thirty-six percent of patients in the first month of the Wegovy pill were new to GLP-1 therapy. Supporting GLP-1 users Supporting GLP-1 users may be done by adding such attributes as protein, fiber, electrolytes for hydration and portion size to product applications

GLP-1 dose conversion chart and safe switching guide Navigating GLP-1 agonist conversions requires more than a simple chart